Indications and uses
Rapid soothing relief of muscle pain at tender points or nerve pain associated with Fibromyalgia and Neuropathy.
Rapid soothing relief of muscle pain at tender points or nerve pain associated with Fibromyalgia and Neuropathy.
Generously apply 3-4 times daily or more often if needed, 3 inches on and around affected area. Massage in until absorbed, reapply before bedtime and in the morning. Use before and after physical activity. Apply immediately for acute trauma injuries (sprain, strain, bruise and impact injuries).
Store at 15° to 30°C (59° to 86°F). Tamper Evident: Do not use if tube is punctured, cut or opened.
Aesculus hippocastanum 6X, Arnica montana 6X, Belladonna 6X, Crotalus horridus 8X, Echinacea 6X, Graphites 6X, Heloderma 8X, Lachesis mutus 8X, Naja tripudians 8X, Rhus toxicodendron 6X, Ruta graveolens 6X
Rapid soothing relief of muscle pain at tender points or nerve pain associated with Fibromyalgia and Neuropathy.
For external use only
Do not apply in eyes.
Keep all medicines out of reach of children.
Use only as directed, see doctor if pain last more than 3 days, new symptoms occur, redness or swelling could indicate a more serious condition.
Always consult a doctor before beginning a self-help regimen if you are taking a prescription medicine.
If swallowed, get medical help or contact a Poison Control Center right away.
Generously apply 3-4 times daily or more often if needed, 3 inches on and around affected area. Massage in until absorbed, reapply before bedtime and in the morning. Use before and after physical activity. Apply immediately for acute trauma injuries (sprain, strain, bruise and impact injuries).
Captex 300 (from coconut fatty acids), Carbopol® Ultrez 10 (from sucrose), Cetyl Alcohol (from coconut oil), Dowicil, Glycerine (Vegetable-based), Hydrokote (palm kernal oil with lecithin), Isopropyl Myristate emollient (from palm seeds), Lipomulse (from coconut fatty acids), Purified Water, Sodium hydroxide, Steareth-12 (from stearic acid cocoa butter)
Store at 15° to 30°C (59° to 86°F). Tamper Evident: Do not use if tube is punctured, cut or opened.
Formulated by: Topical BioMedics, Inc.
Rhinebeck, NY 12572 1-845-871-4900
MyPainAway™ Fibro Cream is a registered trademark of Topical BioMedics, Inc.
Homeopathic
Contains Arnica
MyPainAway™
Fibro Cream
To Relieve Pains Assoicated with Fibromyalgia and Neuropathy
3% of all Fibro Cream sales donated to Fibromyalgia Research Foundations
Powerd by Topricin®
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 61500-5587-3 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d1-157b-f424-e053-dadaa90a57ce | My Pain Away Fibro Cream Drug Facts |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 61500-5587-3 | My Pain Away | 88 mL in 1 TUBE | CREAM | 88 | 1 |
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 61500-5587 | MY PAIN AWAY (AESCULUS HIPPOCASTANUM, ARNICA MONTANA, BELLADONNA, CROTALUS HORRIDUS, ECHINACEA, GRAPHITES, HELODERMA, LACHESIS MUTUS, NAJA TRIPUDIANS, RHUS TOXICODENDRON, RUTA GRAVEOLENS) CREAM [TOPICAL BIOMEDICS, INC.] | 1 | Legacy NDC, 1 package rows | 20141007_714315cd-573e-47de-9f5c-f482240eb387.zip |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| AESCULUS HIPPOCASTANUM FLOWER | ACTIVE INGREDIENT | KK0Z92II8M | 1 | |
| ARNICA MONTANA | ACTIVE INGREDIENT | O80TY208ZW | 1 | |
| ATROPA BELLADONNA | ACTIVE INGREDIENT | WQZ3G9PF0H | 1 | |
| CROTALUS HORRIDUS HORRIDUS VENOM | ACTIVE INGREDIENT | YHA2XLJ956 | 1 | |
| ECHINACEA ANGUSTIFOLIA | ACTIVE INGREDIENT | VB06AV5US8 | 1 | |
| GRAPHITE | ACTIVE INGREDIENT | 4QQN74LH4O | 1 | |
| HELODERMA HORRIDUM VENOM | ACTIVE INGREDIENT | O9M1UQ4YIO | 1 | |
| LACHESIS MUTA VENOM | ACTIVE INGREDIENT | VSW71SS07I | 1 | |
| NAJA NAJA VENOM | ACTIVE INGREDIENT | ZZ4AG7L7VM | 1 | |
| RUTA GRAVEOLENS FLOWERING TOP | ACTIVE INGREDIENT | N94C2U587S | 1 | |
| TOXICODENDRON PUBESCENS LEAF | ACTIVE INGREDIENT | 6IO182RP7A | 1 | |
| AESCULUS HIPPOCASTANUM FLOWER | ACTIVE MOIETY | KK0Z92II8M | 1 | |
| ARNICA MONTANA | ACTIVE MOIETY | O80TY208ZW | 1 | |
| ATROPA BELLADONNA | ACTIVE MOIETY | WQZ3G9PF0H | 1 | |
| CROTALUS HORRIDUS HORRIDUS VENOM | ACTIVE MOIETY | YHA2XLJ956 | 1 | |
| ECHINACEA ANGUSTIFOLIA | ACTIVE MOIETY | VB06AV5US8 | 1 | |
| GRAPHITE | ACTIVE MOIETY | 4QQN74LH4O | 1 | |
| HELODERMA HORRIDUM VENOM | ACTIVE MOIETY | O9M1UQ4YIO | 1 | |
| LACHESIS MUTA VENOM | ACTIVE MOIETY | VSW71SS07I | 1 | |
| NAJA NAJA VENOM | ACTIVE MOIETY | ZZ4AG7L7VM | 1 | |
| RUTA GRAVEOLENS FLOWERING TOP | ACTIVE MOIETY | N94C2U587S | 1 | |
| TOXICODENDRON PUBESCENS LEAF | ACTIVE MOIETY | 6IO182RP7A | 1 | |
| CETYL ALCOHOL | INACTIVE INGREDIENT | 936JST6JCN | 1 | |
| COCONUT ACID | INACTIVE INGREDIENT | 40U37V505D | 1 | |
| GLYCERIN | INACTIVE INGREDIENT | PDC6A3C0OX | 1 | |
| ISOPROPYL MYRISTATE | INACTIVE INGREDIENT | 0RE8K4LNJS | 1 | |
| PALM KERNEL OIL | INACTIVE INGREDIENT | B0S90M0233 | 1 | |
| QUATERNIUM-15 CIS-FORM | INACTIVE INGREDIENT | LIT014L4RH | 1 | |
| SODIUM HYDROXIDE | INACTIVE INGREDIENT | 55X04QC32I | 1 | |
| STEARETH-12 | INACTIVE INGREDIENT | 51J36A59E0 | 1 | |
| SUCROSE | INACTIVE INGREDIENT | C151H8M554 | 1 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 1 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 61500-5587 | 61500-5587-3 |
Every source-derived ingredient row is available through these pages.
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION / INTRAVITREAL | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | SOLUTION / NASAL | 20 mg | ||
| ISOPROPYL MYRISTATE | ISOPROPYL MYRISTATE | 0RE8K4LNJS | LOTION / TOPICAL | 50 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | AEROSOL / TOPICAL | 3 %w/w | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | SUSPENSION/ DROPS / AURICULAR (OTIC) | ADJ PH | ||
| ISOPROPYL MYRISTATE | ISOPROPYL MYRISTATE | 0RE8K4LNJS | AEROSOL, FOAM / TOPICAL | 144 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | OINTMENT, AUGMENTED / TOPICAL | 0.11 %w/w | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | GEL / OPHTHALMIC | 0.88 %w/w | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, SOLUTION / SUBCUTANEOUS | 1 %w/v | ||
| COCONUT ACID | COCONUT ACID | 40U37V505D | SOLUTION / TOPICAL | 0.7 %w/w | ||
| CETYL ALCOHOL | CETYL ALCOHOL | 936JST6JCN | AEROSOL / TOPICAL | 1.16 %w/w | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | FILM, EXTENDED RELEASE / TRANSDERMAL | 0.85 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SUSPENSION/ DROPS / ORAL | 750 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / SUBCUTANEOUS | 308 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | CREAM / VAGINAL | 0.19 %w/w | ||
| SUCROSE | SUCROSE | C151H8M554 | CONCENTRATE / ORAL | 4800 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOLUTION / OPHTHALMIC | 6 %w/v | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION / INTRACAUDAL | ADJ PH | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | TABLET, CHEWABLE / ORAL | 12 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | SOLUTION/ DROPS / TOPICAL | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION / INTRASPINAL | ADJ PH | ||
| CETYL ALCOHOL | CETYL ALCOHOL | 936JST6JCN | SUSPENSION / AURICULAR (OTIC) | 1 %w/v | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | PASTE / DENTAL | 20 %w/w | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION / INTERSTITIAL | ADJ PH | ||
| CETYL ALCOHOL | CETYL ALCOHOL | 936JST6JCN | CREAM / VAGINAL | 200 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | PASTE / DENTAL | 0.6 %w/w | ||
| ISOPROPYL MYRISTATE | ISOPROPYL MYRISTATE | 0RE8K4LNJS | SPRAY / TOPICAL | 3665 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | FILM, EXTENDED RELEASE / TRANSDERMAL | 306.2 mg | ||
| ISOPROPYL MYRISTATE | ISOPROPYL MYRISTATE | 0RE8K4LNJS | OIL / AURICULAR (OTIC) | 36 mg | ||
| ISOPROPYL MYRISTATE | ISOPROPYL MYRISTATE | 0RE8K4LNJS | CREAM / VAGINAL | 50 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SUPPOSITORY / RECTAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | SOLUTION / RECTAL | 35.42 %w/v | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | SOLUTION / OPHTHALMIC | 0.05 %w/v | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 78.36 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION / RETROBULBAR | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | SOLUTION / PERIODONTAL | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, SUSPENSION / INTRA-ARTICULAR | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, SUSPENSION, LIPOSOMAL / INTRAVENOUS | ADJ PH | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOLUTION / ORAL | 32400 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE, COATED PELLETS / ORAL | 59.8 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | TABLET / ORAL | 42 mg | ||
| ISOPROPYL MYRISTATE | ISOPROPYL MYRISTATE | 0RE8K4LNJS | AEROSOL, SPRAY / TOPICAL | 6.89 %w/w | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | ELIXIR / ORAL | ADJ PH | ||
| SUCROSE | SUCROSE | C151H8M554 | WAFER / ORAL | 155.2 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | CAPSULE, COATED / ORAL | 0.08 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | SOLUTION / TOPICAL | 39 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, POWDER, FOR SUSPENSION / INTRAVENOUS | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | LOTION, AUGMENTED / TOPICAL | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION / SUBCUTANEOUS | 31.45 mg | ||
| ISOPROPYL MYRISTATE | ISOPROPYL MYRISTATE | 0RE8K4LNJS | OINTMENT / TOPICAL | 35 %w/w | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION / INTRACARDIAC | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION / INTRAPLEURAL | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | POWDER / RESPIRATORY (INHALATION) | ADJ PH | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, COATED / ORAL | 516.42 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | LIQUID / INTRAVENOUS | ADJ PH | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE, DELAYED RELEASE / ORAL | 955 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, POWDER, FOR SOLUTION / PARENTERAL | ADJ PH | ||
| SUCROSE | SUCROSE | C151H8M554 | LIQUID / ORAL | 37500 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | GEL / TOPICAL | 70 mg | ||
| CETYL ALCOHOL | CETYL ALCOHOL | 936JST6JCN | SUSPENSION / OPHTHALMIC | 0.5 %w/v |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| e77e7b72-847e-48df-93cc-3e20bdd234dd | 714315cd-573e-47de-9f5c-f482240eb387 | 2014-06-20 | Warnings | e77e7b72-847e-48df-93cc-3e20bdd234dd 714315cd-573e-47de-9f5c-f482240eb387 |
Adverse event summaries are temporarily unavailable. Other product information remains available.